Gasparetto, C., Lentzsch, S., Schiller, G. J., Callander, N. S., Tuchman, S., Bahlis, N. J., … Lipe, B. (2020). Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, Natalie Scott Callander, Sascha Tuchman, Nizar J. Bahlis, Darrell White, et al. “Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Gasparetto C, Lentzsch S, Schiller GJ, Callander NS, Tuchman S, Bahlis NJ, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Gasparetto, Cristina, et al. “Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Gasparetto C, Lentzsch S, Schiller GJ, Callander NS, Tuchman S, Bahlis NJ, White D, Chen C, Baljevic M, Sutherland HJ, Kotb R, Sebag M, LeBlanc R, Venner CP, Bensinger W, Rossi AC, Sheehan H, Arazy M, Kai K, Lipe B. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2020.